Your Vote Matters! Cast Your Vote for ATA’s Board of Director Candidates 2017…
President-elect and 3 Directors

Voting is via electronic media. Please submit your votes by October 10, 2017.

The ATA Board of Directors (BOD) is pleased to present the approved recommendations for BOD Candidates 2017 made by the ATA Nominating Committee. The nominating committee, chaired by Dr. David Steward, put out the Call for Nominations in the 2016 Program Book, several issues of Thyroid, ATA SIGNAL Member e-News.

By the deadline of March 31, 2017, ATA members submitted a record-setting 58 nominations. Through a rigorous process candidates were selected following a request from the Board for researchers, clinicians, oncologists and pathologists.

The Ballot will open via electronic media September 1, 2017 and will close on October 10, 2017.

Candidates for the 2017 ATA Ballot:

➤ President-elect Candidates — Vote for One (1)
   James Hennessey, MD ........................................................... page 2
   Elizabeth Pearce, MD ........................................................... page 2

➤ ATA Directors
   (Vote for Three (3) Total — One (1) in Each Category)

   • Researcher Director — Vote for One (1)
     Antonio Di Cristofano, PhD .............................................. page 4
     Douglas Forrest, PhD ....................................................... page 4

   • Clinician Director — Vote for One (1)
     Andrew Gianoukakis, MD ............................................... page 6
     Megan Haymart, MD ........................................................ page 6

   • Oncologist, Pediatric Endocrinologist, or Pathologist Director — Vote for One (1)
     Keith Bible MD, PhD (Oncologist) .................................... page 8
     Thomas Giordano, MD, PhD (Pathologist) ......................... page 8
ATA President-elect — Candidate Statements and Biosketches

The president-elect has a one-year term of office (2017–2018), followed by one-year term as president (2018–2019) and one-year term as a past-president (2019–2020); Vote for One (1)

James Hennessey, MD
Candidate for President-elect

Candidate Statement

I joined ATA in 1989 providing my first service on the Education Committee, as a member, then Chair from 1999-2001 producing the first collection of common patient brochures. I served on the Patient Education and Advocacy committee, and was an ATA representative to the Thyroid Foundation of America from 2002-5. I have served the Public Health Committee since 2004, previously serving as Chair. I was elected to the ATA Board of Directors and served from 2012-2016. I have served on the editorial boards of Thyroid, Endocrine Practice and the Journal of Clinical Endocrinology and Metabolism. I represented ATA on the joint AACE/ATA 2012 guidelines for evaluation and treatment of hypothyroidism. I represented ATA before the FDA on issues of L-thyroxine bioequivalence. I have published two summaries of the data collected through the ATA Pharmacovigilance website.

I believe the ATA plays a pivotal role in providing clinical balance between ongoing advances in basic knowledge of thyroid pathophysiology and the application of new diagnostic and therapeutic approaches to the evaluation of outcomes of new and current therapies. I favor ATA as the global leader in thyroid health. Our role allows us to apply the ever changing facts of discovery for the benefit of people with thyroid disease. To this end, I advocate for ATA to be the patient-preferred resource for education and information pertaining to thyroid disease. The ATA’s integrative work creates an opportunity to catalyze innovative, meaningful, and fundable thyroid research upon which we would create clinical practice standards based on the best available evidence. This makes it possible to communicate these advances to the wider physician community for the benefit of all thyroid patients. As president I would strive to represent all active clinicians and researchers to maintain a balance in the Association’s activities, increasing our financial viability to expand ATA programs and directing our ultimate attention to improving the care of our patients.

Biosketch

Dr. James V. Hennessey is Director of Clinical Endocrinology at Beth Israel Deaconess Medical Center in Boston, MA. He is an Associate Professor of Medicine at the Harvard Medical School.

Elizabeth Pearce, MD
Candidate for President-elect

Candidate Statement

It is a tremendous honor to be nominated as a candidate for president-elect. I consider the ATA to be my professional home. I value ATA meetings for their collegiality and scientific rigor. The ATA is fortunate to have a superb staff and an amazingly energetic and motivated membership.

Among the goals articulated in the 2015 ATA strategic plan is the establishment of an integrative process to catalyze innovative, meaningful, and fundable thyroid research. In the current painfully depressing climate for grant support, the ATA needs to serve as a strong and vocal advocate for the value of thyroid-related research funding. Innovation often is stimulated by cross-pollination across disciplines, and it is critically important to continue to foster the ATA as an organization which is fully inclusive of a diverse membership encompassing the whole spectrum of thyroid research and clinical care. In order for the ATA to continue to thrive it is essential to nurture thyroid careers for young people; the Ridgeway Trainees Conference and trainee tracks at the annual meeting do a wonderful job of introducing young scientists and clinicians to the ATA, but new ways of maintaining that relationship once training is completed could be explored. Another goal outlined in the 2015 strategic plan is to expand the ATA’s visibility as the global leader in thyroid health. The ATA already has a wealth of educational resources for both patients and clinicians, but it may be possible to find ways to broaden available topics and platforms in order to reach new audiences. The ATA could take a greater role in partnering with sister organizations to support thyroid-related public health efforts both nationally and globally (for example in the area of iodine nutrition, a passion of mine). Finally, continued discussion is needed regarding how ongoing updates and modern methodology can best be incorporated in the clinical guidelines development process.

Thank you for your consideration. I am excited about this opportunity to serve the ATA.

Biosketch

Elizabeth N. Pearce, MD, MSc is an Associate Professor of Medicine at Boston University School of Medicine in the Section of Endocrinology, Diabetes, and Nutrition. She
American Thyroid Association Candidates for President-elect and Directors 2017

James Hennessey, MD, continued

School. Born in Middletown Connecticut USA, he completed undergraduate medical training at the Medical Faculty of the Karl Franzens University in Graz Austria. He served as an Intern and Medical Resident at the New Britain Hospital (UCONN) in New Britain Connecticut. He entered active duty with the USAF Medical Corps as an Internist/Flight Surgeon after residency and later completed subspecialty training in endocrinology and metabolism at the Walter Reed Army Medical Center in Washington DC where he conducted research in thyroxine bioequivalence.

Following fellowship Dr Hennessey served as the Chief of Endocrinology at USAF Medical Center Wright-Patterson in Ohio and later joined the faculty at Wright State University School of Medicine appointed as the Director of Clinical Clerkships. He maintained a clinical-teaching practice in endocrinology at Wright State and in thyroidology as a reserve medical officer at the Wright-Patterson Medical Center where he again served on active duty during Operation Desert Storm. Upon arrival at Brown Medical School in Providence RI, he transferred to the Air National Guard as a flight surgeon, was promoted to Colonel, the Rhode Island State Air Surgeon and finally State Surgeon, retiring after a 25 year USAF career in 2006. While at Brown, he served as Associate Director for Clinical Education in the Division of Endocrinology at Rhode Island Hospital where he played a major role in the endocrine fellowship program and directed the Brown Medical School Endocrine Pathophysiology course.

Dr Hennessey’s career has focused on the clinical education of medical students, resident physicians in internal medicine, and fellows in endocrinology and metabolism. In this capacity he has conducted lectures, precepted clinical care, and carried out original and sponsored clinical research with his trainees. Currently, he is pursuing his clinical interest in thyroid disease with expanding clinical programs.

Elizabeth Pearce, MD, continued

received her undergraduate and medical degrees from Harvard and a masters’ degree in epidemiology from the Boston University School of Public Health. She completed her residency in internal medicine at Beth Israel Deaconess Medical Center, and her fellowship in endocrinology at Boston University under the mentorship of Dr. Lewis Braverman. Her research interests include the sufficiency of dietary iodine in the U.S. and globally; thyroid function in pregnancy; thyroidal effects of exposure to environmental endocrine disruptors; and the cardiovascular effects of subclinical thyroid dysfunction. She has been part of the leadership of the Iodine Global Network (IGN; formerly ICCIDD) since 2009. She is a member of the AACE Thyroid Scientific Committee and serves as faculty for the Endocrine Society’s annual board review course. She has served on multiple editorial boards, including those for Endocrine Practice; Journal of Clinical Endocrinology and Metabolism; Clinical Endocrinology; European Journal of Clinical Nutrition; and Lancet Diabetes & Endocrinology.

Dr. Pearce has been a member of the American Thyroid Association since 2000. She has chaired both the ATA’s Publications and Public Health Committees. She co-chaired the 2012 annual meeting Program Committee, co-chaired the spring symposia in 2009 and 2016, and was a member of the program committee for the 2015 International Thyroid Congress. She has served as a member of the Finance Committee, and currently is a member of the Guidelines Policy Task Force. She was one of the leaders of the effort to establish the ATA’s Braverman lectureship. She co-chaired the task force for the 2017 Pregnancy Guidelines. She is an Associate Editor for both Thyroid and Clinical Thyroidology. She served as a member of the Board of Directors from 2009–2013. Dr. Pearce was the 2011 recipient of the American Thyroid Association’s Van Meter Award for outstanding contributions to research on the thyroid gland.
Antonio Di Cristofano, PhD
Candidate for Researcher Director
Category — Board of Directors

Candidate Statement
It is a great honor to be nominated as a candidate for the ATA Board of Directors.

Since joining the Association in 2008, I’ve found the ATA to be not only a unique platform to meet and interact with fellow laboratory scientists interested in thyroid disorders, but also and especially an invaluable interface with the clinical research community.

As demonstrated by my ongoing service in the Research Committee, I am deeply dedicated to promoting basic and translational thyroid research.

As a Director, I would like to continue to help the ATA grow and support its basic science membership and increase efforts to foster basic and translational thyroid-related research.

I believe that ATA’s mission to prevent and treat thyroid disease through excellence in research cannot be fully accomplished without a much stronger and better coordinated basic and translational science component to guide and inform innovative and effective clinical research.

Improved outreach efforts to attract new laboratory-based members, increased and targeted fundraising efforts to support not only seed projects from new and established investigators, but also new postdoctoral fellowships to train the next generation of thyroidologists, improved and streamlined resource-sharing within the thyroid research community, and increased advocacy to promote thyroid research recognition and support from federal sources would be among the priorities I would like to sponsor as a member of ATA Board of Directors.

Biosketch
Antonio Di Cristofano received his PhD in Cellular and Molecular Genetics from the University of Naples, Italy, and completed his postdoctoral training at Memorial Sloan Kettering Cancer Center. After starting his independent career as a faculty of the Fox Chase Cancer Center in Philadelphia, in 2008 he was recruited by the Albert Einstein College of Medicine (Bronx, NY), where he is a Professor of Developmental and Molecular Biology.

His general area of expertise is cancer biology and signaling. His work has made contributions to the elucidation

Douglas Forrest, PhD
Candidate for Researcher Director
Category — Board of Directors

Candidate Statement
I am honored to be nominated as Research candidate for the Board of Directors. A key attraction of the ATA is its broad vision, which incorporates excellence in research as part of its mission alongside clinical care, education and public health. I would work to promote research in thyroid biology and thyroid disease, in the interests of all members and in keeping with the overall mission of the ATA.

I am personally indebted to the ATA leadership who in years past had the vision to integrate research into the society’s goals. This open-minded philosophy attracted me to the ATA as a welcoming home for scientifically rigorous research. The creation and communication of knowledge weaves through all activities of a vibrant society. My background in interdisciplinary, collaborative research and my previous service in the ATA would allow me, if elected, to work constructively on the board.

The ATA provides a unique forum that brings together the spectrum of basic, translational and clinical research in the thyroid field. In a world of vast amounts of scientific information, the ATA plays a crucial role in bringing new evidence and concepts to its members and the wider community. In an era of rapid technological change, the ATA should be poised to adapt to emerging technologies and the opportunities they present.

Research depends upon investigators and trainees with inquisitive minds entering our field. I support initiatives for funding thyroid research and for making the ATA a platform that helps to build careers. The Ridgway Trainee’s Conference supports clinical and basic tracks but there is scope for growth in research content. We recently initiated a half-day Ridgway research symposium, which may be expanded into a full-day, intensive research program. I would strive to enhance these and other attractions of the ATA and in so doing, hopefully also attract new members. Thank you for your consideration.

Biosketch
Douglas Forrest is Senior Investigator in the Laboratory of Endocrinology and Receptor Biology at the National Institute of Diabetes and Digestive and Kidney Disease at the National Institutes of Health (NIH). He received his PhD at Glasgow
Antonio Di Cristofano, PhD, continued

of the key role played by the PI3K signaling cascade in the pathogenesis of follicular and anaplastic thyroid cancer.

His NCI-funded research is focused on the identification of the genetic, metabolic, and signaling changes associated in vivo with thyroid cancer progression and resistance to targeted therapy using sophisticated genetically modified mouse models.

A member of the ATA since 2008, Dr. Di Cristofano was the recipient of the 2012 American Thyroid Association Van Meter Award. He is a member of the American Cancer Society Tumor Biochemistry and Endocrinology Study Section, of the Editorial Board of Endocrine-Related Cancer, and serves on the ATA Research Committee and Anaplastic Thyroid Cancer Guidelines Task Force.

Douglas Forrest, PhD, continued

University for studies on feline leukemia virus. His interest in thyroid hormone was first sparked during training at the European Molecular Biology Laboratory in Heidelberg and Karolinska Institute in Stockholm. Thyroid research has ever since remained the main focus of his career.

In the United States, Dr. Forrest previously held faculty appointments as Assistant Professor then Associate Professor at the Department of Human Genetics at Mount Sinai School of Medicine. His experience includes teaching and obtaining NIH and international grants. He has served on grant study sections and on the editorial boards of \textit{Thyroid}, \textit{Endocrinology}, \textit{Molecular Endocrinology} and \textit{Frontiers in Endocrinology}. He has mentored trainees who have pursued careers in independent research, clinical practice, industry and scientific administration.

Dr. Forrest’s research interests concern thyroid hormone in mammalian development and disease with emphasis on basic and translational studies of thyroid hormone receptors and deiodinase enzymes. His contributions have been recognized with the Van Meter Award of the American Thyroid Association and Merck Prize of the European Thyroid Association; he has presented the Shizume Lecture of the Japanese Thyroid Association and Pitt-Rivers Lecture of the British Endocrine Society.

As a member of the ATA since 1999, Dr. Forrest has served on the Annual Meeting Program Committee, Awards Committee, Planning Committee for the Spring Summit on “The thyroid in pregnancy and development” and the Basic Research Guidelines Task Force. He co-authored the “ATA Guide to investigating thyroid hormone economy and action in rodent and cell models”. He was co-chair with Elizabeth Pearce of the 82nd Annual Meeting in Quebec City. He currently serves on the Trainee Career and Advancement Committee as chair of the Basic Track and is a keen advocate for all trainees in the thyroid field.
American Thyroid Association Candidates for President-elect and Directors 2017

Andrew Gianoukakis, MD
Candidate for Clinician Category — Board of Directors

Candidate Statement
It has been a great pleasure and privilege to serve the ATA as an active member since 1997, and I feel honored to now be nominated for a position on the ATA Board of Directors. The ATA is an organization that leads the way in discovery, patient care and patient education, however our organization’s greatest strength is that it fosters an environment of collegiality, collaboration and mentorship amongst a diverse group of clinicians and scientists from multiple specialties; a truly multidisciplinary society. As the former chair of the ATA Trainee and Career Advancement Committee and co-chair of the annual ATA Trainee Conference, I have witnessed these attributes of our members and organization firsthand. ATA leadership has pioneered and supported trainee programs since the early 90’s and every ATA member ever called upon to share his or her knowledge and experience has always done so with a passion. I am very proud to be a member of such an organization and if elected to serve on the board of directors I will do my best to maintain and further enhance the mission of this great society.

Biosketch
Andrew G. Gianoukakis MD is a Professor of Medicine in the Geffen School of Medicine at UCLA. Dr. Gianoukakis completed his Internal Medicine training and Endocrinology and Metabolism fellowship at The Albany Medical College. He subsequently joined the faculty of the Albany Medical College before moving on to Harbor-UCLA Medical Center in Los Angeles. Dr. Gianoukakis is a clinician educator and clinical researcher. With regard to teaching, Dr. Gianoukakis serves as the program director of the Harbor-UCLA Endocrinology and Metabolism training program where he oversees the training of 11 subspecialty trainees enrolled in a 2 or 3-year fellowship program. He also serves on the Association of Program Directors in Endocrinology and Metabolism (APDEM) council since 2015. He served as co-chair of the annual ATA Clinical Trainee Track from 2009-2013 and as a Track participant from 2007-2013. Dr. Gianoukakis has served on the ATA Trainee and Career Advancement Committee as a member since 2008 and as Chair of the committee from 2011-14. Furthermore, Dr. Gianoukakis has co-chaired and participated in the ATA E. Chester Ridgway Trainee Conference since its inception in 2014. As a clinician,

Megan Haymart, MD
Candidate for Clinician Category — Board of Directors

Candidate Statement
It is an honor to be nominated as a candidate for the ATA Board of Directors. It would be a privilege to serve in a leadership role for an organization that has been so instrumental in my career trajectory. I attended my first ATA meeting 11 years ago as an endocrine fellow. At that initial meeting, I was immediately impressed by the collegiality of the members and the quality of the science.

Since becoming an ATA member, I have attended every national meeting, presented my research at numerous meetings, served on the editorial board for Thyroid and as Associate Editor for VideoEndocrinology, helped create a consensus review, attended leadership meetings to discuss the ATA’s future, served on the ATA Public Health Committee (2010-2012), served on the ATA Finance and Audit Committee (2012-current), and served as the ATA Finance and Audit Committee Chair (2016-current).

Eleven years later and I am now prepared to give back to the thyroid community by serving on the ATA Board of Directors. If I am elected to the ATA Board of Directors, I will work hard to continue to build our ATA community. This includes making it a welcoming and rich environment for trainees and fellows, as fellows are the future of the ATA. It also includes supporting our colleagues and junior faculty members involved in thyroid research, including supporting and disseminating basic, clinical, and health services research. Ultimately, the goal underlying our research and our national meetings is to better serve the patient. Therefore, continuing our efforts to be “the source” of thyroid information for our patients is both interwoven into our mission and is key to our future. Finally, I want the ATA to continue to be a community that supports each other, grows, and diversifies its representation.

Thank you for your consideration.

Biosketch
Megan R. Haymart, MD, is Associate Professor of Medicine in the Division of Metabolism, Endocrinology, and Diabetes and Hematology/Oncology at the University of Michigan. She obtained her MD degree from Johns Hopkins Medical School. She completed her Internal Medicine Residency at Johns Hopkins Hospital and her Endocrinology Fellowship at the University of Wisconsin.
Andrew Gianoukakis, MD, continued

Dr. Gianoukakis heads the thyroid unit at Harbor-UCLA Medical Center and directs the Thyroid Nodule Aspiration clinic and Thyroid Oncology clinic. Dr. Gianoukakis’ research interests include thyroid cancer as well as autoimmune thyroid disease. He directs a research team performing phase II-III clinical thyroid cancer trials and studies. He is a member of the International Thyroid Oncology Group (ITOG) where he serves as a member of the Board of Directors as well as chair of ITOG’s Membership Committee. Additionally, Dr. Gianoukakis serves as secretary of the Southern California Thyroid Cancer Consortium (SCThyCC), and advisory board member of the National Graves’ Disease and Thyroid Foundation (GDATF) and the Thyroid Cancer Survivors Association (ThyCa).

Megan Haymart, MD, continued

Dr. Haymart’s clinical focus is thyroid cancer and thyroid nodules as she works with a multidisciplinary endocrine oncology team at the University of Michigan. Dr. Haymart’s research focuses on variation in the management of thyroid disorders with an emphasis on the role of patients, providers, and health systems in treatment decision making. With R01 funding from the National Cancer Institute (NCI) of the National Institutes of Health (NIH), she is currently evaluating treatment decision making in low-risk thyroid cancer. With R01 funding from the Agency for Healthcare Research and Quality (AHRQ), she is investigating the role of imaging in the overdiagnosis of low-risk thyroid cancer. Dr. Haymart is the recent recipient of the University of Michigan’s Jerome Conn Award for Research Excellence. In addition to her clinical efforts and research endeavors, Dr. Haymart is involved in creating the National Comprehensive Cancer Network (NCCN) thyroid carcinoma guidelines. She is also active in the American Thyroid Association and the Endocrine Society as she currently serves as the Chair for the American Thyroid Association Finance and Audit Committee and is on the Endocrine Society’s Annual Meeting Steering Committee. She has also served on the editorial boards for Thyroid (2013-current), the Journal of Clinical Endocrinology and Metabolism (JCEM) (2013-2016), and Endocrine Today (2017-current). She is also Associate Editor for VideoEndocrinology (2014-2017).
Keith Bible MD, PhD
(Oncologist)
Candidate for Oncologist, Pediatric Endocrinologist, or Pathologist Category — Board of Directors

Candidate Statement
I look forward to continued service to the American Thyroid Association, viewing my candidacy for election to the ATA Board of Directors as a natural extension of my prior and ongoing commitment to this very important organization and to its missions. The ATA takes on increasing relevance as we approach its 95th year, reflecting not only an organization of physicians and researchers, but also of specialized nurses, Nurse Practitioners and Physician’s Assistants. Moreover, the roles of the ATA have been expanding to ever more directly impact trainee and patient education alike, and the ATA continues to be THE go-to organization for Thyroidologists.

Having served as a member of both the ATA Thyroid Nodules and Differentiated Thyroid Cancer and the Anaplastic Thyroid Cancer Guidelines Task Forces, I appreciate the important role of the ATA in taking the lead in developing evidence-based - as well as practical and relevant - guidelines that are easily accessible to providers. Serving as the co-chair of the second iteration of the Anaplastic Thyroid Cancer Guidelines Task Force, I am also now experiencing the impact of mandated guidelines clearing houses of guidelines development, and working to pilot navigation through the ever more rigorous requirements for guidelines. Having also served the ATA as a member of the Ethics Advisory Committee, I have additionally come to understand mission-critical issues related to personal and organizational conflict of interest, and the importance that the ATA maintain the highest level of institutional ethical standards; this is another issue to which I am devoted.

If elected to the Board, my priorities will also include working to further expand educational outreach not only to members and to trainees, but also to other providers including to nurses, Nurse Practitioners, and to Physician’s Assistants. I aspire also to bolster involvement of subspecialists across a broad array of disciplines, including within my own specialty, medical oncology.

Biosketch
Keith C. Bible, M.D., Ph.D. is a Medical Oncologist, Professor of Oncology, and Chair of the Endocrine Malignancies Disease Group of the Mayo Clinic Cancer Center at Mayo Clinic in Rochester, Minnesota; 80% of

Thomas Giordano, MD, PhD
(Pathologist)
Candidate for Oncologist, Pediatric Endocrinologist, or Pathologist Category — Board of Directors

Candidate Statement
Over the last decade we have witnessed significant advances in our understanding of thyroid disease, especially thyroid cancer. Much of the progress is attributable to developments in technology and laboratory science, and is, in part, a consequence of the substantial effort to sequence the human genome in the 1990s. Technology has since advanced to the point where it is now possible to rapidly and efficiently query the genome, transcriptome, methylome, and proteome of diseased tissues. Advances in technology underpin the current precision medicine initiative, which has already been deployed to further the understanding of thyroid disease.

In the field of thyroid cancer, application of omic technologies has led to advances in understanding cancer initiation and progression, and improvements in patient care through enhanced diagnostic and prognostic assessment. More progress will certainly follow. At the center of precision medicine is pathology, its natural home, as the vast majority of precision medicine is nothing more than advanced laboratory testing. Thus, pathology will be essential for the thyroid field to realize the full potential of personalized medicine.

For over 20 years as a surgical and molecular pathologist at Michigan, I have worked closely with colleagues in endocrinology on patient care, education and collaborative research projects. I was privileged to directly participate in the application of genomic science to the field of thyroid cancer. Serving as co-chair of the TCGA study on papillary carcinoma has provided me a perspective that will help inform the future of thyroid disease. In addition, my role as Director of the Division of Molecular and Genomic Pathology further enriches my knowledge in this rapidly evolving area.

The ATA, as a leading organization in thyroid biology and disease, would certainly benefit from perspective provided by an accomplished leader in pathology to advance its missions in research, patient care, education, and public health. I possess the necessary skills and background to serve the ATA as a member of its Board of Directors.

Biosketch
Dr. Giordano received his B.A. from Johns Hopkins
ATA Board of Directors — Candidate Statements and Biosketches

The Director has a four-year term of office (2017–2021).
Vote for three (3) total — one (1) in each category.

**Keith Bible MD, PhD, continued**

his clinical time is devoted to the care of patients with advanced endocrine cancers, primarily thyroid cancers. His research focuses on developing improved therapeutic approaches for patients afflicted with advanced endocrine cancers. Dr. Bible has moreover led an NIH-funded laboratory targeting bench-to-bedside-to-bench translational research linked to his multicenter therapeutic clinical trials, including in differentiated, medullary and anaplastic thyroid cancer.

Dr. Bible completed his medical degree at the University of Illinois, and then his Ph.D. in chemistry at the University of Illinois in Urbana-Champaign. Thereafter, Dr. Bible completed clinical training in Internal Medicine, Hematology and Oncology, as well as a Fellowship in Cancer Pharmacology, before joining the Mayo Clinic staff. In addition to serving the ATA on the Thyroid Nodules and Differentiated Thyroid Cancer and the Anaplastic Thyroid Cancer Guidelines Task Forces, he also serves as a member of the ATA Ethics Advisory Committee. Dr. Bible is also a member of the Board of Directors and serves on the Protocol Committee of the International Thyroid Oncology Group (ITOG). He is also a member of the Endocrine Society, as well as of the American Society of Clinical Oncology (ASCO); he previously also served on several NIH Study Sections, and was a Charter Member of the Developmental Therapeutic Study Section of the National Cancer Institute (NCI).

**Thomas Giordano, MD, PhD, continued**

University in 1983 and earned his M.D. and Ph.D. through a combined program at Rutgers University and UMDNJ - Robert Wood Johnson Medical School. His graduate studies in the department of Microbiology involved gene expression regulation. He completed residency training in Anatomic Pathology at the National Cancer Institute and fellowship training in Oncologic Pathology at Memorial Sloan-Kettering Cancer Center. Both residency and fellowship training permitted extensive exposure to endocrine pathology. After AP training, he joined the faculty of the Department of Pathology at the University of Michigan Medical School as Assistant Professor, was promoted to Associate Professor in 2001, and Professor in 2008. In 2015, he became the Henry Clay Bryant Professor of Pathology. He also holds a joint appointment in the Metabolism and Endocrinology Division of the Department of Internal Medicine.

Dr. Giordano is an endocrine and molecular pathologist with long-standing interests in thyroid and adrenocortical neoplasia. His specific academic interests in thyroid cancer include molecular and genomic profiling and tumor classification. Recently, he served as co-chair of The Cancer Genome Atlas Papillary Thyroid Carcinoma project, which he led from its initiation to publication in Cell in 2014. He also was instrumental in convincing the TCGA leadership to conduct their Adrenal Cortical Carcinoma project and again he served as co-chair of this study until its publication in Cancer Cell in 2016. He also served on the Analysis Working group for the TCGA Pheochromocytoma project, which was also published in Cancer Cell in 2017. He is currently serving on the TCGA Steering committee for their PanCancerAtlas project, the goal of which is to collectively evaluate the genomics of all tumors studied by TCGA.

Dr. Giordano regularly attends the ATA Annual Meeting and has participated on their Tumor Board for the last two years. He is a member of the ATA Laboratory Services Committee and ATA Anaplastic Thyroid Cancer (ATC) Guidelines Task Force.